Trial Profile
An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Therapeutic Use
- Acronyms THETIS
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Feb 2019 Status changed from active, no longer recruiting to completed.
- 08 May 2018 Planned End Date changed from 31 Jan 2019 to 17 Jan 2019.
- 09 Jul 2016 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.